Page 1

Total revenue of $ 25.8 million , up $ 8.8 million , or 52 % , year - over - year . Gross margin of 72.5 % , up approximately 250 basis points year - over - year . Exhibit 99.1 Venus Concept Announces Second Quarter 2021 Financial Results ; Increases Fiscal Year 2021 Revenue Guidance TORONTO , August 13 , 2021 ( PR Newswire ) - Venus Concept Inc. ( " Venus Concept " or the " Company " ) ( NASDAQ : VERO ) , a global medical aesthetic technology leader , announced financial results for the three and six months ended June 30 , 2021 . Second Quarter 2021 Summary & Recent Highlights : GAAP operating income of $ 1.5 million , up $ 10.3 million , or 117 % , year - over - year . GAAP net income attributable to stockholders of $ 0.4 million , up $ 13.5 million , or 103 % , year - over - year . VENUSCONCEPT Adjusted EBITDA of $ 0.5 million , up $ 3.2 million , or 117 % , year - over - year . On July 20 , 2021 , the Company announced that it received a medical device license issued by Health Canada to market the Venus Fiore Feminine Health System in Canada . Collaboration with Venus Williams for Venus Bliss has generated significant increase in visits to B2B and B2C websites , accelerating sales process and driving consumer adoption . Venus Concept is pleased to announce AlmeTM , the new commercial brand name for Robocor , the development project for our next generation robotic technology for medical aesthetic applications . New product development progress Venus Bliss Max , next - generation platform for full body contouring ; continue to target submission for FDA 510k submission by end - Q3'21 . Management Commentary : " We delivered second quarter revenue results that exceeded our expectations , and reflect strong execution of our focused commercial strategy and continued improvements in the operating environment , " said Domenic Serafino , Chief Executive Officer of Venus Concept . " Total revenue increased 14 % quarter - over - quarter , driven primarily by a 17 % sequential increase in total subscription and systems revenue , and a 21 % sequential increase in sales to customers in the U.S. We are very encouraged by the strong execution from our global sales team in the second quarter . We believe our performance in the second quarter represents continued evidence that our targeted commercial strategy has us well positioned to return to above - market growth as the global aesthetics and hair restoration markets continue to recover as we progress through 2021. " Mr. Serafino continued : “ Our second quarter subscription and systems revenue results , combined with the substantial increase in our pipeline , led to the increase in our full year 2021 guidance which now calls for total revenue in the range of $ 102.0 million to $ 107.0 million , representing an increase of approximately 31 % to 37 % , year - over - year . We continue to expect to drive strong operating leverage in 2021 , as well . Importantly , the longer - term outlook for the Company is compelling as we continue to make progress in the area of product development including our efforts to develop the next generation robotic technology for medical aesthetic applications . "